Detalhe da pesquisa
1.
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.
J Geriatr Psychiatry Neurol
; 31(2): 90-96, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29562810
2.
Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.
J Biol Chem
; 289(25): 17732-46, 2014 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24808179
3.
PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Arterioscler Thromb Vasc Biol
; 34(12): 2700-5, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25278291
4.
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
J Biol Chem
; 287(52): 43492-501, 2012 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-23105118
5.
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.
J Biol Chem
; 285(52): 40965-78, 2010 Dec 24.
Artigo
Inglês
| MEDLINE | ID: mdl-20937814
6.
The 9p21.3 locus and cardiovascular risk in familial hypercholesterolemia.
J Clin Lipidol
; 11(2): 406-412, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28502497
7.
Polyvinylalcohol three-dimensional matrices for improved long-term dynamic culture of hepatocytes.
J Biomed Mater Res A
; 66(3): 562-70, 2003 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12918039
8.
PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
PLoS One
; 8(8): e72113, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23951290